locus can be classified dichotomously (susceptible versus nonsusceptible genotype), this will create 2 10 (>1,000) possible strata. Classification based on just 20 genes will produce more than one million strata. This is methodologically challenging, especially considering interactions of these genes with other genes and environmental factors 2 . No single cohort study, no matter how large, will have adequate power to detect gene-environment interaction for numerous gene variants, especially for rarer health outcomes. Appropriate pooled analyses will increase the chance of finding true associations of relevance to public health. The full potential of cohort studies to shed light on the occurrence of complex diseases will probably be realized only by pooling and synthesis across multiple populations with different genetic, environmental and sociocultural factors. Integrating data across studies will require developing approaches for facilitating pooled analyses and synthesis. We are seeing the beginning of such a global movement across international boundaries with the establishment of P3G by Bartha Knoppers and her colleagues (Public Population Project in Genomics; http://www.p3gconsortium.org/index.cfm).
Second, we need systematic integration of all human genome epidemiology studies. To build our knowledge base on human genes and health, we need to carry out different types of epidemiologic studies and synthesize their results. Epidemiologic studies can be cohort, case-control or cross-sectional in nature. The strengths and limitations of each design are well-known 3 . Cohort studies are often erroneously perceived as inherently superior to case-control studies. Given the large variation in funds and time needed to conduct cohort studies, every effort should be made to conduct case-control studies that are based on a valid population sampling scheme of newly diagnosed cases in welldefined communities and appropriately selected controls. Well-designed populationbased incident case-control studies can even be nested in a larger population cohort or population under surveillance 4 .
To develop a systematic approach to the integration of epidemiologic data on human genes, the Human Genome Epidemiology Network (HuGENet; http://www.cdc.gov/ genomics/hugenet/default.htm) was launched in 1998. This network of individuals and organizations continuously assesses the impact of human genome variation on population health. HuGENet develops and applies systematic approaches to build the global knowledge base on genes and diseases. In May 2004, the network has more than 700 collaborators from 40 different countries. Its website featured 26 reviews of specific gene-disease associations. In addition, HuGENet has continuously abstracted epidemiologic articles on human genes in an online searchable database, by gene, outcome and risk factor. Because of the tendency for publication bias, an ongoing serious systematic evaluation is now needed for published and unpublished data.
Third, we need evidence-based processes that use epidemiologic information. The synthesis of epidemiologic and biologic data should lead to an evidence-based process that assesses the value of genomic information in health care and disease prevention. For example, an interaction between factor V Leiden (FVL) and use of oral contraceptives has been documented (joint relative risk of 30; ref. 5). But the absolute risk is relatively low (28 per 10,000 person-years) among women with FVL who use oral contraceptives. Whether it is beneficial to screen women for FVL before prescribing oral contraceptives is unclear. Venous thrombosis is relatively rare, and mortality from venous thrombosis is low in young women 6 . For healthy women contemplating using oral contraceptives, the risk-benefit equation would not currently favor screening 7 . This
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example illustrates that epidemiologic data need to be collected to inform clinical trials and decision-making for health practice. As single cohort studies are carried out around the world, we can begin to synthesize the incomplete epidemiologic knowledge base for use in policy and practice. These reviews will also uncover gaps in our knowledge base that can be filled by new research from ongoing studies.
It is time that we develop a global public health genomics initiative that builds on the currently fragmented efforts of geneticepidemiologic research around the world. This initiative can be developed through public-private-academic collaborations. In particular, we need to build a robust process that allows data from many biobanks to be integrated through standardized platforms for joint analyses. Also, we need to integrate data obtained from all valid epidemiologic study designs, notably population-based incident casecontrol studies. Systematic synthesis of epidemiologic data takes time and skills and should be allocated sufficient resources. This proposed initiative can take us a long way towards translating human genome discoveries into population health benefits for citizens of the twenty-first century. The sequences of NMB0066 and ermC of pIM13 are identical, whereas that of ermC of pE5 contains one nonsynonymous mutation and an insertion of 107 nucleotides upstream of the open reading frame. This means that, although NMB0066 is clearly horizontally acquired by N. meningitidis MC58, its origin remains at best obscure. In addition, it is implausible that the surrounding genes, NMB0065 through NMB0070, were acquired in one event from the same donor as ermC, opposing the authors' suggestion that they were transferred simultaneously with NMB0066. In conclusion, although the algorithm by Nakamura and coworkers correctly identified the acquisition of NMB0066 by N. meningitidis, their suggestion that S. aureus was the donor organism is improbable. Moreover, their interpretation concerning the simultaneous acquisition of NMB0066 and its surrounding genes is inappropriate. 
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